Market Overview

Kite Pharma Is Up Because Of This Slideshow

Kite Pharma Is Up Because Of This Slideshow
Related KITE
Gilead Looking To Buy Incyte? It Makes Sense
RBC Hints At Potential M&A For Kite Pharma
The Vetr community has downgraded $KITE to 3-Stars (Vetr)

Kite Pharma Inc (NASDAQ: KITE) is trading higher on Wednesday after the company presented at the 2015 Jefferies Now at the Immuno-Oncology Summit in Boston.

The company has been a solid performer in 2015, and is up 120 percent in the past year.

In the presentation, Kite Pharma discussed everything from an expanding pipeline to its plan to "transform cancer therapy." In particular, the company highlights its TCRs, which are aimed at what it calls "a broad spectrum of therapeutic tumor targets.

"Kite Pharma is uniquely positioned to address an unmet need and target a large hidden opportunity," it adds.

Check out the full slides below.

Kite Corporate Presentation 4-15-15 - Jefferies Immuno-Oncology Summit

Latest Ratings for KITE

Mar 2017Standpoint ResearchDowngradesBuyHold
Mar 2017Stifel NicolausDowngradesBuyHold
Mar 2017CitigroupDowngradesBuyNeutral

View More Analyst Ratings for KITE
View the Latest Analyst Ratings

Posted-In: Immuno-Oncology Summit In BostonAnalyst Color Biotech News Events Analyst Ratings Movers General Best of Benzinga


Related Articles (KITE)

View Comments and Join the Discussion!